N-glycosides, Polymers Thereof, Metal Derivatives (e.g., Nucleic Acids, Oligonucleotides, Etc.) Patents (Class 536/22.1)
  • Patent number: 10214555
    Abstract: In this method, an oligonucleotide is prepared by using, as a synthesis unit, a novel nucleoside monomer compound represented by formula (I) [wherein X, R1, Y, Base, Z, Ar, R2, R3 and n are each as defined in Claim 1]. The novel nucleoside monomer compound is a nucleoside, the base moiety of which is substituted with an aromatic-hydrocarbon-ring-carbonyl or -thiocarbonyl group having at least one hydrophobic group. The method cars dispense with column-chromatographic purification in every reaction, and enables base elongation not only in the 3?-direction but also in the 5?-direction, thus attaining efficient liquid-phase mass synthesis of an oligonucleotide.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: February 26, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITJED
    Inventors: Mitsuru Nonogawa, Toshiaki Nagata, Hideki Saito, Tsuneo Yasuma
  • Patent number: 9738681
    Abstract: A compound represented by the general formula (III) which serves as an intermediate of an oligonucleotide analog having stable and excellent antisense or antigene activity or having excellent activity as a detection reagent (probe) for a specific gene or as a primer for the initiation of amplification of a specific gene can be produced at high yields regardless of the type of nucleobase by a method comprising reacting a compound represented by the general formula (II) or a salt thereof with a trimethylsilylated compound obtained from a compound represented by the general formula (IVb), wherein X, Y, Z, A, R, and B are as defined in claim 1.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: August 22, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Koji Morita, Miho Sato
  • Patent number: 9410196
    Abstract: Various embodiments of the present disclosure generally relate to molecular biological protocols, equipment and reagents for the sequencing of target nucleic acid (DNA, RNA, cDNA, etc) molecules.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: August 9, 2016
    Assignee: QUANTUMDX GROUP LIMITED
    Inventor: Jonathan O'Halloran
  • Patent number: 9370589
    Abstract: The present invention provides a novel fluorescent nanoparticle imaging probe having a switching function (a function to quench a fluorescent dye during nanoparticle preparation, and emit fluorescence during imaging). A switching fluorescent nanoparticle probe comprising: a molecular assembly composed of an amphiphilic block polymer having a hydrophilic block chain and a hydrophobic block chain; and a fluorescent dye encapsulated in the molecular assembly, wherein (a) the hydrophilic block chain comprises, as an essential hydrophilic structural unit, a unit selected from a sarcosine unit and an alkylene oxide unit, (b) the hydrophobic block chain comprises, as an essential hydrophobic structural unit, a unit selected from the group consisting of an amino acid unit and a hydroxylic acid unit, and (c) the fluorescent dye is a cyanine compound represented by the formula (I): and two or more molecules of the fluorescent dye are encapsulated in the single molecular assembly.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: June 21, 2016
    Assignees: SHIMADZU CORPORATION, KYOTO UNIVERSITY
    Inventors: Isao Hara, Eiichi Ozeki, Hideo Saji, Shunsaku Kimura, Masahiro Ono, Takashi Temma
  • Patent number: 9359601
    Abstract: The present invention features a number of methods for identifying one or more compounds that bind to a biological target. The methods include synthesizing a library of compounds, wherein the compounds contain a functional moiety having one or more diversity positions. The functional moiety of the compounds is operatively linked to an initiator oligonucleotide that identifies the structure of the functional moiety.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: June 7, 2016
    Assignee: X-Chem, Inc.
    Inventor: Richard W. Wagner
  • Patent number: 9339536
    Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 17, 2016
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
  • Patent number: 9334301
    Abstract: A nucleic acid construct, a method of preparing a nanoparticle by using the nucleic acid construct, and a nanoparticle and nanoparticle complex prepared using the method. Various types of metal nanoparticles may be efficiently prepared using the template for preparing a nanoparticle and the nanoparticle prepared using the template.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: May 10, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventor: No-kyoung Park
  • Patent number: 9291597
    Abstract: Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: March 22, 2016
    Assignee: VENTANA MEDICAL SYSTEMS, INC.
    Inventors: Rui Hong, Hong Wang, Mark Lefever, Jan Froehlich, Christopher Bieniarz, Brian Kelly, Phillip Miller
  • Patent number: 9284343
    Abstract: Disclosed are O-protected compounds of the formula (I): wherein B is an optionally protected nucleobase, and R1-R3 are as described herein, wherein at least one of R1-R3 is —CH2—O—N?CHR. The compounds are useful as intermediates in oligonucleotide synthesis. Also disclosed is a method of preparing the compounds from nucleosides via a process comprising conversion of a hydroxyl group to a methylthiomethoxy group, and a method of preparing oligonucleotides such as RNA starting from the compounds. The —CH2—O—N?CHR group is stable during oligonucleotide synthesis and can be easily removed after synthesis via, for example, treatment with a base.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: March 15, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Serge L. Beaucage, Jacek Cieslak
  • Patent number: 9217173
    Abstract: This invention relates to a process for synthesis of a cDNA in a sample, in an enzymatic reaction, wherein the process comprises the steps: simultaneous preparation of a first enzyme with polyadenylation activity, a second enzyme with reverse transcriptase activity, a buffer, at least one ribonucleotide, at least one deoxyribonucleotide, an anchor oligonucleotide; addition of a sample that comprises a ribonucleic acid; and incubation of the agents of the previous steps in one or more temperature steps, which are selected such that the first enzyme and the second enzyme show activity. The invention further relates to a reaction mixture that comprises a first enzyme with polyadenylation activity, a second enzyme with reverse transcriptase activity, optionally a buffer, optionally at least one ribonucleotide, optionally at least one deoxyribonucleotide, and optionally an anchor oligonucleotide. Moreover, the invention relates to a kit that comprises a corresponding reaction mixture.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: December 22, 2015
    Assignee: QIAGEN GMBH
    Inventors: Holger Engel, Subrahmanyam Yerramilli, Martin Kreutz, Dirk Loeffert, Christian Korfhage
  • Patent number: 9206216
    Abstract: Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: December 8, 2015
    Assignee: Pierce Biotechnology, Inc.
    Inventors: Christopher L. Etienne, Kay K. Opperman, Barbara J. Kaboord, Scott Meier, Jean-Samuel Schultz
  • Patent number: 9193752
    Abstract: Provided herein are novel 5?-(S)—CH3 substituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the furanose ring of each of the novel 5?-(S)—CH3 substituted bicyclic nucleosides includes a 2? to 4? bridging group. The 5?-(S)—CH3 substituted bicyclic nucleosides are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as for example increasing the binding affinity. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: November 24, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Thazha P. Prakash, Charles Allerson, Balkrishen Bhat, Punit P. Seth, Eric E. Swayze
  • Patent number: 9102726
    Abstract: The present invention provides methods of using soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases caused by the dysfunction or undesired function of a cellular immune response involving T cells. The invention moreover provides soluble CD83 proteins, specifically suited for said purpose, nucleic acids and vectors encoding said CD83 proteins, cells transformed/transfected with the nucleic acids or vectors, methods for producing said CD83 proteins, pharmaceutical compositions containing said CD83 proteins, nucleic acids or vectors, and antibodies against said soluble CD83 proteins and assay methods and kits comprising said antibodies.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: August 11, 2015
    Assignee: ARGOS THERAPEUTICS, INC.
    Inventors: Alexander Steinkasserer, Matthias Lechmann, Elisabeth Zinser
  • Patent number: 9097724
    Abstract: The number of atoms present in an ion of a molecule is identified using a mixture of different forms of the molecule. A mass spectrometer analyzes a mixture of at least two forms of the molecule using one or more ion scans producing a mass spectrum. The first form of the molecule includes a first combination of isotopes of one or more elements. The second form of the molecule includes a second combination of isotopes of the one or more elements. A first peak and a second peak that differ in mass by a multiple of a mass difference between the first combination of isotopes and the second combination of isotopes are located in the mass spectrum. The number of atoms of the one or more elements present in an ion of the molecule is identified from a mass difference between the first peak and the second peak.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: August 4, 2015
    Assignee: DH Technologies Development Pte. Ltd.
    Inventors: Ronald F. Bonner, Stephen A. Tate
  • Publication number: 20150147752
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
  • Patent number: 9040501
    Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: May 26, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Sergel Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
  • Patent number: 9040250
    Abstract: A composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6. A method of administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock a composition having a proanthocyanidin. A method of administering to a patient diagnosed with a gram negative bacterial infection a composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6.
    Type: Grant
    Filed: August 2, 2007
    Date of Patent: May 26, 2015
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: James B Delehanty, Brandy J White, Baochuan Lin, Frances S Ligler
  • Publication number: 20150141637
    Abstract: The present invention provides novel tricyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in double stranded compositions. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 21, 2015
    Applicant: UNIVERSITÄT BERN
    Inventors: Christian Leumann, Branislav Dugovic, Jory Liétard
  • Publication number: 20150140120
    Abstract: Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto.
    Type: Application
    Filed: October 3, 2014
    Publication date: May 21, 2015
    Applicant: ARCHEMIX LLC
    Inventors: Dilara McCauley, John L. Diener, Charles Wilson, Thomas Greene McCauley
  • Publication number: 20150141320
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 9029084
    Abstract: A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: May 12, 2015
    Assignee: Qiagen Manchester Limited
    Inventors: David Mark Whitcombe, Nicola Jo Thelwell, Paul Francis Ravetto
  • Patent number: 9017938
    Abstract: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 28, 2015
    Assignee: Advanced Accelerator Applications
    Inventor: Massimo Zollo
  • Patent number: 9012144
    Abstract: The invention provides methods for sequencing a polynucleotide comprising stopping an extension cycle in a sequence by synthesis reaction before the reaction has run to near or full completion.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: April 21, 2015
    Assignee: Fluidigm Corporation
    Inventors: Stanley Lapidus, Philip Richard Buzby, Timothy Harris
  • Patent number: 9005892
    Abstract: The present invention relates to methods and reagents for detecting analytes, e.g. nucleic acids. The new methods and reagents allow a simple and sensitive detection even in complex biological samples.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 14, 2015
    Assignee: Baseclick GmbH
    Inventors: Thomas Carell, Anja Schwögler, Glenn A. Burley, Johannes Gierlich, Mohammad Reza Mofid
  • Patent number: 9005935
    Abstract: The present invention provides new compositions for transposase-mediated fragmenting and tagging DNA targets. The invention relates to the surprising discovery that use of manganese ions (Mn2+) in transposase reactions improves the transposase reaction. It also relates to the surprising discovery that Mg2+ ions can be used in a transposase reaction with wild-type and/or engineered transposases at levels much higher than previously thought. The invention provides for the use of naturally-occurring transposases in in vitro reactions, as well as improved schemes for cleaving, tagging, and amplifying target DNA.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: April 14, 2015
    Assignee: Agilent Technologies, Inc.
    Inventor: Alexander S. Belyaev
  • Publication number: 20150099791
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of UTRN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of UTRN. Methods for modulating expression of UTRN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of UTRN.
    Type: Application
    Filed: May 16, 2013
    Publication date: April 9, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachussetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 8999673
    Abstract: Provided is a method for selectively obtaining, for a given target gene, a “joined DNA fragment” wherein just a target gene fragment is joined with desired other DNA fragments, regardless of whether a DNA fragment containing a target gene sequence has been purified. In the provided method, a double-stranded joining DNA fragment containing a sequence A and/or a sequence B is selectively joined to the ends of a target gene fragment. A mixture of a double-stranded gene fragment, the 3? end of which is protruding, and the double-stranded joining DNA fragment, which are related in a prescribed manner, undergoes at least two cycles of thermal denaturation, reassociation, and DNA synthesis, resulting in a “joined DNA fragment,” which is a double-stranded DNA fragment including at least one instance of a sequence resulting from joining sequence A, the target gene sequence, and sequence B. A “single-side joined DNA fragment” can also be obtained, by a similar method.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: April 7, 2015
    Assignee: National University Corporation University of Toyama
    Inventors: Nobuyuki Kurosawa, Masaharu Isobe
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Patent number: 8993245
    Abstract: The present invention encompasses a method for detecting a target comprising a repeating epitope.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: March 31, 2015
    Assignees: Mediomics, LLC, Saint Louis University
    Inventors: Tomasz Heyduk, Ling Tian
  • Patent number: 8993238
    Abstract: Compositions and methods related to transgenic glyphosate tolerant Brassica plants are provided. Specifically, the present invention provides Brassica plants having a DP-073496-4 event which imparts tolerance to glyphosate. The Brassica plant harboring the DP-073496-4 event at the recited chromosomal location comprises genomic/transgene junctions within SEQ ID NO: 2 or with genomic/transgene junctions as set forth in SEQ ID NO: 12 and/or 13. The characterization of the genomic insertion site of the event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the event are provided.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: March 31, 2015
    Assignees: E I du Pont de Nemours and Company, Pioneer Hi Bred International Inc
    Inventors: David George Charne, Wenpin Chen, Chadwick Bruce Koscielny, Zhongsen Li, Jayantilal Patel, Ferdinand G Thoonen, Lomas Tulsieram, Yongping Zhang
  • Patent number: 8993528
    Abstract: The present disclosure provides tricyclic nucleosides, oligomeric compounds comprising at least one of the tricyclic nucleosides and methods of using the oligomeric compounds. The methods provided herein include contacting a cell or administering to an animal at least one of the oligomeric compounds. In certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Punit P. Seth, Thazha P. Prakash
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
  • Patent number: 8987431
    Abstract: Essential genes coding for the metabolic pathway of solventogenic autotrophic Clostridia were sequenced, and functionality was confirmed. The present invention utilizes a comparative inter-species approach to develop the minimum set of essential genes for metabolic function and estimate productivity in species of suspected solventogenic capability.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: March 24, 2015
    Assignee: Coskata, Inc.
    Inventors: Andrew Reeves, Fenglin Yin
  • Patent number: 8986933
    Abstract: A process for detecting human rhinovirus nucleic acid in a biological sample, includes producing an amplification product by amplifying an human bocavirus nucleotide sequence using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and measuring said amplification product to detect human rhinovirus in said biological sample. Also provided are reagents and methods for detecting and distinguishing human rhinovirus from other viruses. A kit is provided for detecting and quantifying human rhinovirus in a biological sample.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: March 24, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Xiaoyan Lu, Dean Erdman
  • Patent number: 8987377
    Abstract: The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: March 24, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Stephanie E. Barrett, Marina Busuek, Steven L. Colletti, Robert M. Garbaccio, Erin N. Guidry, Robert A. Kowtoniuk, Jing Liao, Craig A. Parish, Rubina G. Parmar, Tao Pei, Kevin M. Schlosser, David M. Tellers, Sandra C. Tobias, Quang T. Truong, Jacob H. Waldman, Weimin Wang, J. Michael Williams
  • Patent number: 8980551
    Abstract: The present invention relates to a method for genotyping DNA molecules contained in at least one DNA sample. The method includes: (a) digesting the DNA molecules contained in at least one DNA sample with a class IIB restriction endonuclease to generate DNA fragments; (b) optionally separating DNA fragments comprising the recognition site for the class IIB restriction endonuclease from the remaining DNA fragments; (c) attaching at least one adaptor DNA to the 5? and/or 3? end of one or both strands of the DNA fragments comprising the recognition site for the class IIB restriction endonuclease obtained in a) or separated in b) to form adaptor-fragment constructs; (d) determining the sequence of at least a fraction of the DNA fragments obtained in c); and (e) assigning genotypes to the at least one DNA sample analyzed based on the sequence data obtained in d).
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: March 17, 2015
    Assignee: Max-Planck-Gesellschaft Zur Forderung der Wissenschaften E.V.
    Inventors: Norman Warthmann, Detlef Weigel
  • Patent number: 8980556
    Abstract: Compositions and methods for determining an increased likelihood of a response to a targeted treatment of a cancer disease including isolating genomic DNA from a patient sample, amplifying a fragment of DNA by means of PCR with a specific pair of amplification primers, determining if the amplified fragment comprises a wildtype sequence or a mutation by means of a High Resolution Melting Analysis (HRM), and correlating the presence or absence of a mutation with an increased likelihood of success of said targeted treatment. Respective primer pairs, compositions and kits are also claimed.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 17, 2015
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Reinhard Buettner, Stefanie Froehner, Sabine Merkelbach-Bruse, Jasmin Ney, Angelika Roesler
  • Patent number: 8980552
    Abstract: The invention describes a method of and kits for isolating and/or purifying nucleic acids, more specifically short-chain nucleic acids such as miRNA, from a nucleic acid-containing starting material, characterized by the following method steps of: (a) binding the nucleic acids to a nucleic acid-binding support material by contacting the starting material with said nucleic acid-binding support material in the presence of at least one chaotropic compound, at least two different detergents and at least one branched and/or unbranched alcohol, preferably isopropanol, with the concentration of said alcohol being 40% (v/v); (b) optionally eluting the bound nucleic acids from the nucleic acid-binding support material. The method of the invention is particularly suitable for purifying circulating, extracellular miRNA from blood.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: March 17, 2015
    Assignee: QIAGEN GmbH
    Inventors: Martin Horlitz, Markus Sprenger-Haussels
  • Patent number: 8981078
    Abstract: An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. 1.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 17, 2015
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee, Xuemei Zhang
  • Patent number: 8975019
    Abstract: A technology is described that is capable of generating high-throughput sequencing (HTS) read length DNA products to accurately and reliably provide exon connectivity information for alternatively spliced isoforms. The method is not limited by the initial size of the isoform as the technology removes the template oligonucleotide sequence and a newly formed full length ligated product provides an HTS-compatible read length sequence that comprises information that corresponds to the consecutive order of the exons in the original template oligonucleotide.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: March 10, 2015
    Assignee: University Of Massachusetts
    Inventors: Phillip D. Zamore, Melissa J. Moore, Christian Roy
  • Publication number: 20150057187
    Abstract: Click nucleic acid monomers and polymers containing such monomers are disclosed. The click nucleic acid monomers include an optionally protected thiol moiety, an optionally protected thiol-click acceptor moiety, and an optionally protected nucleobase (NB), which in some examples is an A, G, T, U, or C nucleobase. In some examples, the click nucleic acid monomer includes a N-vinyl thiol acetamide (VTA) backbone. In other examples the click nucleic acid monomer includes a N-vinyl thiol ethylamine (VTE) backbone. Methods of using such polymers, for example in place of naturally occurring nucleic acid polymer applications, such as DNA or RNA, and synthetic nucleic acid polymer applications, such as PNA or morpholino nucleic acids, are also disclosed.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 26, 2015
    Inventors: Christopher N. Bowman, Christopher J. Kloxin, Weixian Xi
  • Patent number: 8962580
    Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: February 24, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, Narayanannair K. Jayaprakash, Muthusamy Jayaraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
  • Patent number: 8962241
    Abstract: The present embodiments relate to engineering imaging probes based on “triggered molecular geometry.” Upon detection of a molecular signal, nucleic acid hairpin monomers assemble an imageable molecular shape with prescribed geometry. In some embodiments the prescribed shape can be imaged directly. In some embodiments, the prescribed shape can serve as a spatial organizer or amplification scheme for other imaging entities, such as fluorophore and fluorescent proteins.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: February 24, 2015
    Assignee: California Institute of Technology
    Inventors: Peng Yin, Niles A. Pierce
  • Patent number: 8957002
    Abstract: A sensor chip and detection device are disclosed. The sensor chip includes a substrate, at least a portion of which is covered by a metal nanoparticle film; a first nucleic acid molecule that is characterized by being able to (i) self-anneal into a hairpin conformation and (ii) hybridize specifically to a target nucleic acid molecule, the first nucleic acid molecule having first and second ends, which first end is tethered to the metal nanoparticle film; and a first fluorophore bound to the second end of the first nucleic molecule. When the first nucleic acid molecule is in the hairpin conformation, the metal nanoparticle film substantially quenches fluorescent emissions by the first fluorophore, and when the first nucleic acid molecule is in a non-hairpin conformation fluorescent emissions by the first fluorophore are surface plasmon-enhanced.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: February 17, 2015
    Assignee: University of Rochester
    Inventors: Benjamin L. Miller, Todd D. Krauss, Lewis J. Rothberg, Hsin-I Peng
  • Patent number: 8957200
    Abstract: The present invention provides novel 3?,5?-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: February 17, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Eric E. Swayze, Stephen Hanessian, Benjamin R. Schroeder
  • Patent number: 8957044
    Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: February 17, 2015
    Assignees: Wake Forest University Health Sciences, Genethon, Children's Medical Center Corporation
    Inventors: Martin K. Childers, Alan H. Beggs, Ana Maria Buj Bello
  • Patent number: 8957201
    Abstract: A method for the prevention or treatment in a mammal of a disease preventable or treatable by the pharmacologically useful antisense or antigene activity of an oligonucleotide analogue or a pharmacologically acceptable salt thereof in the body of said mammal, which method comprises administering to said mammal in need of such prevention or treatment a pharmaceutically effective amount of an oligonucleotide analogue comprising two or more nucleoside units, wherein at least one of said nucleoside units is a structure of the formula (2): wherein A is methylene; and B is an unsubstituted purin-9-yl, an unsubstituted 2-oxo-pyrimidin-1-yl or a substituted purin-9-yl; or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: February 17, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Masakatsu Kaneko, Koji Morita, Takeshi Imanishi
  • Patent number: 8957191
    Abstract: This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside linkages and one or more cationic moieties and said zwitterionic nucleotides further comprise either one or more hydrophobic moieties or one or more TEE's with the general structure (I) Hydrophobic element-pH-responsive hydrophilic elements (I).
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: February 17, 2015
    Assignee: Steffen Panzner
    Inventor: Steffen Panzner
  • Patent number: 8951790
    Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: February 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventor: Deba P. Saha
  • Patent number: 8945833
    Abstract: The present invention relates to a method for determining drug resistance mutations in any of the non-structural protein regions NS3 to NS5B of Hepatitis C Virus (HCV) for genotypes 1 to 6, more in particular for subtype specific genotypes 1a, 1b, 2a, 2b, 3a, 4a and 4d.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: February 3, 2015
    Inventors: Lieven Jozef Stuyver, Diana Koletzki, Jan Martin Berke, Ina Isabel Vandenbroucke, Leen Roger Vijgen